

Supplemental Digital Content 12. Table: Clinical and demographic characteristics of COVID-19 patients above 1 year of age per SARS-CoV-2 variant phase

Characteristic	Individual phases					Omicron/Population Immunity versus other phases		
	Wild-type, N = 48	Alpha, N = 9	Delta, N = 30	Omicron, N = 50	Population Immunity, N = 6	WT/Alpha/Delta, N = 87	Omicron/Population immunity, N = 56	p-value
Age (continuous)	11.9 (3.9, 15.5)	15.3 (11.3, 16.8)	6.9 (2.6, 14.4)	4.8 (2.3, 12.0)	9.6 (7.0, 10.0)	11.3 (3.1, 15.5)	5.9 (2.7, 11.6)	0.041
Medical history present	75% (36/48)	66% (6/9)	77% (23/30)	61% (30/49)	66% (4/6)	75% (65/87)	62% (34/55)	0.20
Abnormal neurocognitive development	19% (9/48)	38% (3/8)	28% (8/29)	20% (10/49)	33% (2/6)	24% (20/85)	22% (12/55)	0.91
History of pulmonary condition	31% (14/45)	0% (0/9)	27% (8/30)	23% (11/47)	33% (2/6)	26% (22/84)	25% (13/53)	0.91
ICU admission	17% (8/48)	11% (1/9)	13% (4/30)	16% (8/50)	0% (0/6)	15% (13/87)	14% (8/56)	0.94
length of hospitalization	3.0 (1.0, 6.2)	3.0 (1.0, 4.0)	4.0 (2.0, 6.0)	2.0 (1.0, 3.0)	2.5 (1.0, 4.8)	3.0 (1.0, 6.0)	2.0 (1.0, 3.0)	0.0054
Severe disease	58% (28/48)	67% (6/9)	60% (18/30)	36% (18/50)	50% (3/6)	60% (52/87)	38% (21/56)	0.034

Clinical characteristics of patients at different SARS-CoV-2 phases. Descriptive statistics are shown for alle individual phases and inferential statistics are presented to test for differences between the pre-omicron variants (wild-type, alpha, and delta) versus omicron and population immunity phases. Continuous values are described with the median and interquartile ranges and the Wilcoxon rank sum test was used for statistical testing. For categorical values the count, numerator and percentage are shown and the Pearson's Chi-squared test was used for statistical testing.